-
Subject Areas on Research
-
8-ISO-PGF2alpha production by alveolar macrophages exposed to hyperoxia.
-
African Ancestry Gradient Is Associated with Lower Systemic F2-Isoprostane Levels.
-
Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study.
-
Effects of 2 years of caloric restriction on oxidative status assessed by urinary F2-isoprostanes: The CALERIE 2 randomized clinical trial.
-
Effects of aerobic training on oxidative status in postsurgical non-small cell lung cancer patients: a pilot study.
-
Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane.
-
F2-isoprostanes: a measure of oxidative stress in children receiving treatment for leukemia.
-
Influence of Inflammatory and Oxidative Stress Pathways on Longitudinal Symptom Experiences in Children With Leukemia.
-
Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation.
-
NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats.
-
Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry.
-
Racial differences in urinary F2-isoprostane levels and the cross-sectional association with BMI.
-
Role of nonenzymatically generated prostanoid, 8-iso-PGF2 alpha, in pulmonary oxygen toxicity.
-
Systemic markers of oxidative status and colorectal adenomatous polyps.
-
Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.
-
Thromboxane receptor signalling in renal ischemia reperfusion injury.
-
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
-
Urinary F2-isoprostanes and metabolic markers of fat oxidation.
-
Urinary F2-isoprostanes and the risk of hypertension.
-
Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes.
-
Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes.
-
Urinary F2-isoprostanes, obesity, and weight gain in the IRAS cohort.
-
Urinary biomarkers of oxidative status in a clinical model of oxidative assault.
-
Urinary biomarkers of oxidative status.